Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
- Revenue in USD (TTM)40.56m
- Net income in USD-218.90m
- Incorporated2017
- Employees168.00
- LocationZentalis Pharmaceuticals Inc10275 Science Center Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 263-4333
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 225.46m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -124.58m | 228.49m | 140.00 | -- | 1.44 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Solid Biosciences Inc | 0.00 | -90.25m | 229.13m | 88.00 | -- | 1.07 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 231.11m | 13.00 | 1.89 | 0.6603 | 7.55 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 233.01m | 135.00 | -- | 8.72 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Renovaro Inc | 0.00 | -53.93m | 233.06m | 11.00 | -- | 1.38 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Sutro Biopharma Inc | 154.07m | -114.96m | 235.57m | 300.00 | -- | 1.84 | -- | 1.53 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 236.66m | 133.00 | -- | 1.28 | -- | 222.43 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Eliem Therapeutics Inc | 0.00 | -14.53m | 237.71m | 9.00 | -- | 1.79 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 247.13m | 168.00 | -- | 0.5387 | -- | 6.09 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Black Diamond Therapeutics Inc | 0.00 | -79.79m | 249.76m | 54.00 | -- | 2.24 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
MeiraGTx Holdings PLC | 11.38m | -74.11m | 258.51m | 402.00 | -- | 2.12 | -- | 22.72 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 260.67m | 449.00 | -- | 10.69 | -- | 14.20 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
MacroGenics Inc | 43.36m | -23.24m | 263.06m | 339.00 | -- | 2.48 | -- | 6.07 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Holder | Shares | % Held |
---|---|---|
Matrix Capital Management Co. LPas of 31 Mar 2024 | 13.96m | 19.66% |
Eventide Asset Management LLCas of 31 Mar 2024 | 11.57m | 16.30% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.61m | 13.54% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.24m | 5.97% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.23m | 5.96% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.79m | 5.33% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.61m | 5.09% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.43m | 4.83% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.32m | 4.67% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 2.82m | 3.97% |